Gensight BiologicsGSGTF 3-Year RORE % is -58.88 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 1,293 Biotechnology companies, Gensight Biologics ranks worse than 85.77% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Gensight Biologics's 3-Year RORE % for the quarter that ended in Dec. 2025 was -58.88%.
The industry rank for Gensight Biologics's 3-Year RORE % or its related term are showing as below:
GSGTF's 3-Year RORE % is ranked worse than 85.77% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs GSGTF: -58.88
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Gensight Biologics 3-Year RORE % Related Terms
Gensight Biologics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSGTF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Gensight Biologics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Gensight Biologics (GSGTF) has a 3-Year RORE % of -58.88 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #1109 out of 1293 companies in the Biotechnology industry, placing it in the top 85.8%.
Is Gensight Biologics' 3-Year RORE % too high?
Gensight Biologics' current 3-Year RORE % is -58.88. Based on the distribution chart, Gensight Biologics ranks #1109 out of 1293 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #1109 out of 1293 companies for 3-Year RORE %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current 3-Year RORE % is -58.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current 3-Year RORE % is -58.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current 3-Year RORE % is -58.88 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 